Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolargin (PRELP) is a small leucine-rich repeat proteoglycan present in the extracellular matrix of connective tissues. It anchors basement membranes to the underlying connective tissue by binding type I collagen (basement membranes) and type II collagen (cartilage), as well as the proteoglycan perlecan. Its N-terminal domain is rich in proline and arginine and binds glycosaminoglycans, mediating cell adhesion and inhibiting osteoclast differentiation. PRELP variants have been implicated in certain disease contexts (e.g., Hutchinson-Gilford progeria, bladder carcinoma in situ), but are not considered direct drug targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prolargin (PRELP).